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DIVERSITY OF ANTIBIOTIC USE AND BACTERIAL
RESISTANCE
Polk R1, Pakyz A2, Oinonen M3
1Virginia Commonwealth University School of Pharmacy, School of
Pharmacy,VA, USA, 2Virginia Commonwealth University, Richmond,
VA, USA, 3University HealthSystem Consortium, Oak Brook, IL, USA
Organization: The University HealthSystem Consortium (UHC;
http://www.uhc.edu) hospitals and Virginia Commonwealth 
University.
Problem or Issue Addressed: Nationwide rates of bacterial resis-
tance among nosocomial pathogens are increasing. Mathemati-
cal models and limited clinical data suggest that greater diversity
(or heterogeneity) of antibiotic use may decrease rates of 
resistance.
Goals: The goal of this investigation is to determine if an increase
in diversity of antibiotic use at UHC hospitals will be associated
with an improvement in rates of resistance. The UHC is an
alliance of 97 academic medical centers and afﬁliated hospitals.
UHC hospitals that also subscribe to the Clinical Resource
Manager program were asked to participate in a long-term, mul-
tihospital antimicrobial use and surveillance program in 2003.
We retrieved claims data for systemic antibiotic use administered
to adult inpatients beginning in year 2002 (N = 31 hospitals) and
through 2005 (N = 35 hospitals). Using 5 classes of antibiotics
that are commonly administered for treatment of nosocomial
infections (aminoglycosides, 3/4th generation cephalosporins,
ﬂuoroquinolones, carbapenems, and b-lactamase inhibitor com-
binations) we applied Simpson’s Index of Diversity (D) to arrive
at a diversity measure for each hospital. We also collected annual
antibiograms from most hospitals for 2002 through 2004, and
we focused on methicillin-resistant Staphylococcus aureus
(MRSA) and ﬂuoroquinolone-resistant Pseudomonas aeruginosa
(FQRPa). We determined both the proportion of resistant iso-
lates (% resistant) and the rate of resistance isolates (no. organ-
isms/1000 admissions) for MRSA and FQRPa. Hospitals with a
Diversity Index less than the median diversity value for year
2004 (i.e., D < 0.722) were offered an educational intervention.
The intervention consisted of a visit to each hospital by the prin-
cipal investigator (PI, REP) at the investigator’s expense. During
the visit, a 45 minute educational presentation was given to the
hospital antibiotic committee regarding the potential merits of
diversity of antibiotic use, and to provide benchmarking infor-
mation regarding diversity and resistance in MRSA and FQRPa
to each hospital.
Outcomes: The hypotheses to be tested and their outcomes
included: 1) Would hospitals extend an offer for the PI to visit
and give a presentation; 2) in response to the intervention, would
hospitals purposefully change antibiotic use toward greater
diversity; and 3) would resistance rates and proportions of resis-
tant MRSA and FQRPa improve following a change toward
greater diversity of use.
Implementation Strategy: An e-mail was sent in the summer of
2006 to pharmacy and infection control personnel at 17 hospi-
tals with low diversity (above). This text of the message included
a brief review of the potential value of diversity, each hospital’s
diversity score and an offer to provide the intervention (above).
The intervention had to occur by the end of 2006, and 5 hospi-
tals responded positively. The last of 5 interventions was made
on 12/5/06.
Results: It is too early to say if hospitals will adopt policies to
change antibiotic use that will result in greater diversity of use
during 2006, but it appears doubtful for the following reasons:
1) The “diversity hypothesis” does not seem to be familiar to
many of the contact persons; 2) the potential beneﬁt of diversity
of antibiotic use is not yet established; only two small-scale
prospective investigations have been published; 3) antibiotic for-
mularies and antibiotic use appear to be driven more by acqui-
sition costs of therapy than by concerns regarding resistance; and
4) programs to implement greater diversity will probably require
an increase in the use of relatively expensive antibiotics, such as
the carbapenems.
Lessons Learned: 1) In retrospect, it may have been preferable
to select hospitals for intervention based on resistance rates (e.g.,
resistance rates greater that the median value), rather than on
diversity of antibiotic use (i.e., D less than the median value).
This strategy may have generated more offers for the interven-
tion. 2) The costs of bacterial resistance are not well studied and
an argument that a reduction in rates of resistance will carry cost
beneﬁts is difﬁcult to make at this time. 3) The methods that can
be used by a hospital that will result in greater diversity of
antibacterial drug use and that are relatively straight-forward
and practical are not yet worked out. Computer guided antimi-
crobial selection will be the most feasible method to implement
greater diversity, but this is not yet commonly available.
In spite of these limitations we will continue to monitor
antibiotic use and rates of resistance through 2009 in order to
examine relationships between diversity of use and changes in
rates of bacterial resistance. In addition we will monitor and
measure other relevant and potentially confounding variables
such as infection control efforts, hospital policy toward antibi-
otic use (e.g., formulary restriction, etc.) and the impact of com-
munity acquired (CA) infections on rates of nosocomial
resistance, such as CA-MRSA.
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Organization: University of California, San Diego Medical
Center
Problem or Issue Addressed: Increasing pharmacy budget &
inappropriate medication use. Rapidly rising inpatient pharmacy
budget, lack of evidence-based guidelines for medication use, and
potentially unsafe medication practices created opportunity for
improvement within the University of California, San Diego
Medical Center (UCSDMC) Inpatient Services.
Goals: Goals for the applied pharmacoeconomics pharmacist
specialist position included “hard-dollar” savings to exceed
180% of salary expense after 1 year. Savings were to include
decreased drug expense only, excluding cost-avoidance. Clinical
outcomes research was to be performed to ensure quality of
patient care was improved or maintained.
Outcomes items used in the decision: Clinical and ﬁnancial out-
comes are being assessed through a unique total cost of patient
care model and multiple medication use evaluation projects.
Ongoing outcomes research is based on medical chart review,
trends in DRG coding data, and true changes in patient expense
tracked through TSI Eclipsys® mainframe hospital data linked
to patient encounter(s). Comparisons will also be made to
reported clinical outcomes at other academic medical centers
using the UHC Clinical Resource Manager Database®.
Implementation Strategy: Initial review of current medication use
practice yielded several ideas for projects with high potential
return on investment. Collaboration with various surgical and
medicine stakeholders resulted in improved medication use
policy, stricter criteria for medication use, and research plans 
to assess outcomes. Enforcement of formulary policy was
achieved through changes in practice supported by theUCSDMC
